442 related articles for article (PubMed ID: 25724523)
41. Activation of AKT by hypoxia: a potential target for hypoxic tumors of the head and neck.
Stegeman H; Kaanders JH; Wheeler DL; van der Kogel AJ; Verheijen MM; Waaijer SJ; Iida M; Grénman R; Span PN; Bussink J
BMC Cancer; 2012 Oct; 12():463. PubMed ID: 23046567
[TBL] [Abstract][Full Text] [Related]
42. Targeting mTOR by CZ415 Inhibits Head and Neck Squamous Cell Carcinoma Cells.
Xie J; Li Q; Ding X; Gao Y
Cell Physiol Biochem; 2018; 46(2):676-686. PubMed ID: 29621758
[TBL] [Abstract][Full Text] [Related]
43. Afatinib radiosensitizes head and neck squamous cell carcinoma cells by targeting cancer stem cells.
Macha MA; Rachagani S; Qazi AK; Jahan R; Gupta S; Patel A; Seshacharyulu P; Lin C; Li S; Wang S; Verma V; Kishida S; Kishida M; Nakamura N; Kibe T; Lydiatt WM; Smith RB; Ganti AK; Jones DT; Batra SK; Jain M
Oncotarget; 2017 Mar; 8(13):20961-20973. PubMed ID: 28423495
[TBL] [Abstract][Full Text] [Related]
44. ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
Yun MR; Choi HM; Kang HN; Lee Y; Joo HS; Kim DH; Kim HR; Hong MH; Yoon SO; Cho BC
Oncogene; 2018 Jan; 37(3):377-388. PubMed ID: 28945228
[TBL] [Abstract][Full Text] [Related]
45. Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake.
Fuereder T; Wanek T; Pflegerl P; Jaeger-Lansky A; Hoeflmayer D; Strommer S; Kuntner C; Wrba F; Werzowa J; Hejna M; Müller M; Langer O; Wacheck V
Clin Cancer Res; 2011 Aug; 17(16):5322-32. PubMed ID: 21712451
[TBL] [Abstract][Full Text] [Related]
46. Differential modulation of PI3K/Akt/mTOR activity by EGFR inhibitors: A rationale for co-targeting EGFR and PI3K in cisplatin-resistant HNSCC.
Liao J; Yang Z; Azarbarzin S; Cullen KJ; Dan H
Head Neck; 2024 May; 46(5):1126-1135. PubMed ID: 38429897
[TBL] [Abstract][Full Text] [Related]
47. Radiosensitization of non-small-cell lung cancer cells and xenografts by the interactive effects of pemetrexed and methoxyamine.
Oleinick NL; Biswas T; Patel R; Tao M; Patel R; Weeks L; Sharma N; Dowlati A; Gerson SL; Fu P; Zhang J; Machtay M
Radiother Oncol; 2016 Nov; 121(2):335-341. PubMed ID: 27838149
[TBL] [Abstract][Full Text] [Related]
48. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
[TBL] [Abstract][Full Text] [Related]
49. JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.
Sen M; Pollock NI; Black J; DeGrave KA; Wheeler S; Freilino ML; Joyce S; Lui VW; Zeng Y; Chiosea SI; Grandis JR
Neoplasia; 2015 Mar; 17(3):256-64. PubMed ID: 25810010
[TBL] [Abstract][Full Text] [Related]
50. Senescence Induction by Combined Ionizing Radiation and DNA Damage Response Inhibitors in Head and Neck Squamous Cell Carcinoma Cells.
Dobler C; Jost T; Hecht M; Fietkau R; Distel L
Cells; 2020 Sep; 9(9):. PubMed ID: 32883016
[TBL] [Abstract][Full Text] [Related]
51. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
[TBL] [Abstract][Full Text] [Related]
52. PI3k inhibitors (BKM120 and BYL719) as radiosensitizers for head and neck squamous cell carcinoma during radiotherapy.
Chuang FC; Wang CC; Chen JH; Hwang TZ; Yeh SA; Su YC
PLoS One; 2021; 16(1):e0245715. PubMed ID: 33471836
[TBL] [Abstract][Full Text] [Related]
53. G-Protein-Coupled Receptor Kinase-Interacting Protein 1 (GIT1) Promotes Head and Neck Squamous Cell Carcinoma Metastases via Activating the PI3K/AKT/mTOR Signal Pathway.
Xu R; Xu R; Wang Y; Wang W; Jiang L; Gong S
Comput Math Methods Med; 2022; 2022():6881932. PubMed ID: 35116073
[TBL] [Abstract][Full Text] [Related]
54. AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo.
Torres MA; Raju U; Molkentine D; Riesterer O; Milas L; Ang KK
Invest New Drugs; 2011 Aug; 29(4):554-61. PubMed ID: 20119866
[TBL] [Abstract][Full Text] [Related]
55. Crizotinib Fails to Enhance the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Xenografts.
Baschnagel AM; Galoforo S; Thibodeau BJ; Ahmed S; Nirmal S; Akervall J; Wilson GD
Anticancer Res; 2015 Nov; 35(11):5973-82. PubMed ID: 26504020
[TBL] [Abstract][Full Text] [Related]
56. Pediatric and adult glioblastoma radiosensitization induced by PI3K/mTOR inhibition causes early metabolic alterations detected by nuclear magnetic resonance spectroscopy.
Agliano A; Balarajah G; Ciobota DM; Sidhu J; Clarke PA; Jones C; Workman P; Leach MO; Al-Saffar NMS
Oncotarget; 2017 Jul; 8(29):47969-47983. PubMed ID: 28624789
[TBL] [Abstract][Full Text] [Related]
57. The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer.
Shukuya T; Yamada T; Koenig MJ; Xu J; Okimoto T; Li F; Amann JM; Carbone DP
J Thorac Oncol; 2019 Jun; 14(6):1061-1076. PubMed ID: 30825612
[TBL] [Abstract][Full Text] [Related]
58. Radiosensitization of head and neck squamous cell carcinoma by a SMAC-mimetic compound, SM-164, requires activation of caspases.
Yang J; McEachern D; Li W; Davis MA; Li H; Morgan MA; Bai L; Sebolt JT; Sun H; Lawrence TS; Wang S; Sun Y
Mol Cancer Ther; 2011 Apr; 10(4):658-69. PubMed ID: 21282353
[TBL] [Abstract][Full Text] [Related]
59. Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo.
Chang KY; Tsai SY; Wu CM; Yen CJ; Chuang BF; Chang JY
Clin Cancer Res; 2011 Nov; 17(22):7116-26. PubMed ID: 21976531
[TBL] [Abstract][Full Text] [Related]
60. Different Impacts of DNA-PK and mTOR Kinase Inhibitors in Combination with Ionizing Radiation on HNSCC and Normal Tissue Cells.
Klieber N; Hildebrand LS; Faulhaber E; Symank J; Häck N; Härtl A; Fietkau R; Distel LV
Cells; 2024 Feb; 13(4):. PubMed ID: 38391917
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
